Thor Medical today announces that it has completed its first full-scale production facility at Herøya.
Ready for start-up this year
Last year, the company decided to invest several hundred million Norwegian kroner in its first industrial facility for the production of isotopes for pharmaceuticals at Herøya Industrial Park in Porsgrunn. The plant, which will produce input materials for 21,000 treatment doses annually and create around a dozen jobs, has now been completed and is ready for start-up later this year.
The decision to proceed with full-scale development in March 2025 was based on positive feedback from pilot production since autumn 2024, combined with secured financing and long-term customer agreements.
“The completion of our first full-scale facility marks a major milestone for Thor Medical and is the result of strong execution by both our team and our partners,” said Jasper Kurth, Chief Executive Officer of Thor Medical ASA.
Thor Medical is now entering the commissioning phase of the plant, including verification of systems and equipment, with production expected to commence in the third quarter of 2026.
Read more Thor Medical press release.
A key component of the Herøya ecosystem
Sverre Gotaas, Head of Herøya Industrial Park AS, emphasised that the completion represents an important milestone not only for the company, but for the region as a whole.
By choosing Herøya for its first full-scale facility, Thor Medical underscores the industrial park’s attractive infrastructure, access to expertise, and its ability to facilitate innovation.
“For us as the owner of the industrial park, it is highly encouraging to see the strong results from the pilot phase now materialise in a full-scale facility that will deliver life-saving components to 21,000 patients annually. This project demonstrates in practice how we can build new Norwegian export industries on the foundation of established expertise,” says Sverre Gotaas.
Text: Tone Brekke tone.brekke@hipark.no
